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ABSTRACT
Each year in the USA there are over 1 million hospital
admissions directly related to heart failure (HF). With
similar rates across Europe, this places a huge
economic burden on healthcare systems globally.
Hospitalisation for HF is associated with poor clinical
outcomes with 25% of patients being readmitted with
signs and symptoms of HF within 1 month of
discharge and 10–20% dying in the 6 months after
discharge. Although hospital admission could be a
sign of disease progression, it is also possible that
some of the treatments given acutely for example,
inotropic therapy, may result in neurohormonal,
haemodynamic and other effects accelerating end-
organ damage and contributing to these poor
outcomes after discharge. In contrast to the treatment
of chronic heart failure (CHF), clinical trials conducted
over the past decade in patients with acute HF (AHF)
have failed to show significant reductions in morbidity
or mortality despite some agents causing beneficial
changes in symptoms. As such, the current treatment
of patients hospitalised with HF is mainly based on
consensus rather than clinical evidence and has
changed little over time. We review RELAX-AHF in the
context of the other key, large-scale AHF trials
conducted over the past 15 years and compare and
contrast study design and outcomes in an attempt to
determine which factors might be associated with a
successful trial in the future.
INTRODUCTION
The reasons for the failure of acute heart
failure (AHF) trials in demonstrating
improvements in outcomes are likely multi-
factorial. One limitation may be the use of
novel molecules with poorly described
pharmacology in congested patients often
with end-organ damage already. Frequently,
phase I and II studies are conducted in
patients with chronic heart failure (CHF)
rather than AHF, and treatments may not
demonstrate the same dose–response rela-
tionships in these two groups. Entry criteria
and patient selection are also important as
the presence of certain comorbidities may
render patients more susceptible to adverse
effects for example, renal toxicity. Finally, the
importance of timing and duration of
therapy should not be underestimated. For
outcomes such as improvement in dyspnoea,
only very early intervention is likely to be suc-
cessful. On the other hand, reduction in
readmission and postdischarge mortality
might be best achieved using an early intra-
venous intervention with continuation of
therapy orally postdischarge.
Until recently, attempts to produce an efﬁ-
cacious treatment for AHF had failed. It is
important to consider why this trial was
apparently successful, compared to previous
attempts with alternative agents. Serelaxin
was associated with a lower rate of renal
adverse events compared with placebo. It
resulted in improvements in measures of dys-
pnoea (albeit small and depending on
imputation), reduction in early worsening
HF events, reduction in troponin, shorter
hospital admissions and reduction in CV and
all-cause mortality. It did, however, fail to
show reduction in hospital readmission rates
for HF or renal failure. These positive out-
comes were aided by: targeting a population
of patients most likely to receive beneﬁcial
effects from a drug based on its properties
and actions and by starting the initiation of
therapy as early as possible.
In this review we discuss the drug itself, the
patient population enrolled and the selec-
tion of end points. The 12 key AHF trials are
summarised in tables 1–3.1–12
THE DRUG
The drug studied in RELAX-AHF was sere-
laxin, a recombinant form of human
relaxin-2. The haemodynamic impact of sere-
laxin has recently been studied in AHF
patients.13 In this study it reduced pulmonary
capillary wedge pressure and pulmonary
artery pressure with concomitant reduction
in systemic and pulmonary vascular resist-
ance. It had no effect on cardiac index and
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Table 1 Comparison of key inclusion/exclusion criteria and end points
OPTIME CHF SURVIVE VERITAS EVEREST PROTECT ASCEND-HF RELAX-AHF
Clinicaltrials.gov Identifier NK NCT00348504 NCT00525707 and
NCT00524433
NCT00071331 NCT00328692 and
NCT00354458
NCT00475852 NCT00520806
Enrolment period July 1997–November
1999
March 2003–December
2004
April 2003–January 2005 October 2003–February
2006
May 2007–January 2009 May 2007–August 2010 October 2009–February
2012
Randomised treatments Milrinone: placebo
(1:1)
Levosimendan: dobutamine
(1:1)
Tezosentan: placebo
(1:1)
Tolvaptan: placebo (1:1) Rolofylline: placebo (2:1) Nesiritide: placebo (1:1) Serelaxin: placebo (1:1)
Inclusion criteria
Age, years ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18
Required history of HF Yes* NR NR Yes† Yes‡ NR NR
Time from presentation to
randomisation, hours
<48 NR <24 <48 <24 <48 <16
LVEF, % <40 ≤30 <40 ≤40 NR <40 Any LVEF
Dyspnoea requirements Incorporated into ‘HF
score’§
At rest At rest+RR ≥24/min At rest or with minimal
exertion¶
At rest or with minimal
exertion
At rest or with minimal
activity
At rest or with minimal
exertion
Other evidence of HF
(including symptoms, signs
and objective measures)
≥3/10 on ‘HF score’§ Insufficient response to IV
diuretics and/or VD+ ≥1 of:
dyspnoea at rest or
mechanical ventilation for
HF; oliguria not due to
hypovolaemia; PCWP
≥18 mm Hg and/or cardiac
index ≤2.2 L/min/m2
≥2 of: elevated BNP or
NT-proBNP; clinical
evidence of pulmonary
congestion/oedema;
pulmonary congestion
on CXR; LVSD (EF
<40% or wall motion
index ≤1.2)
≥2 of: dyspnoea; jugular
venous distension;
pitting oedema (>1+)
Requiring IV diuretic
therapy+≥1 of: JVP
>8 cm; pulmonary rales
≥1/3 above base;
peripheral oedema (≥2
+); pre-sacral oedema
≥1 of: RR ≥20/min;
pulmonary rales ≥1/3
above base+≥1 of
pulmonary congestion on
CXR; BNP ≥400 pg/mL
(or NT-proBNP ≥1000);
EF <40%; PCWP
>20 mm Hg
Pulmonary congestion
on
CXR+BNP ≥350 pg/mL
(or NT-proBNP
≥1400 pg/mL)
IV diuretic required before
randomisation
No No Yes No Yes No Yes
Exclusion criteria
Systolic BP, mm Hg <80 or >150 <85 <100 (or <120 if after
VD)
<90 <90 or ≥160 <100 (or <110 if after VD)
or >180
≤125
Serum creatinine, mg/dL >3.0 >5.0 ≥2.5 >3.5 NR NR NR
eGFR, mL/min/1.73 m2 NR NR NR NR <20 or >80 mL/min CC NR <30 or >75
Vasopressors/inotropes Both Inotropes** None None Both Both†† Both
Acute MI/ACS Evidence of unstable
angina, myocardial
ischaemia, or MI within
3 months
NR STEMI; On-going
myocardial ischaemia or
PCI/CABG during
current admission
STEMI at time of
hospitalisation
Evidence of ACS in
2 weeks before
screening
ACS as primary diagnosis;
ECG with new
ST-elevation >1 mm in 2
consecutive leads
Diagnosis of
ACS<45 days before
screening; troponin >3
times upper limit of
normal
Primary end point(s)
Cumulative days of
hospitalisation for CV
cause within 60 days
after therapy
All-cause mortality in the
180 days after therapy
Change from baseline in
dyspnoea over 24 h after
therapy; Incidence of
death or worsening HF
at day 7
Composite score of
changes from baseline
in global clinical status
and body weight at day
7 or discharge
Treatment success,
treatment failure or no
change in the patient’s
condition
Change in dyspnoea 6
and 24 h after therapy;
rehospitalisation for HF
and all-cause death after
therapy to day 30
Change in dyspnoea
from baseline to day 5;
moderately or markedly
improved dyspnoea
from baseline at 6, 12
and 24 h
Continued
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Table 1 Continued
OPTIME CHF SURVIVE VERITAS EVEREST PROTECT ASCEND-HF RELAX-AHF
Secondary end point(s)‡‡
Proportion of treatment
failures due to adverse
events 48 h after
therapy; proportion of
patients achieving
target doses of
ACE-inhibitor therapy
All-cause mortality during
the 31 days following
therapy; mean change in
plasma BNP level from
baseline to 24 h
Incidence of death or
major CV events at
30 days; length of initial
hospital admission
Changes in dyspnoea at
day 1 from baseline;
global clinical status at
day 7 or discharge
All-cause death and
rehospitalisation for CV
or renal causes through
day 60; proportion of
patients who developed
persistent renal
impairment
Self-reported overall
well-being, measured 6
and 24 h after therapy;
composite of worsening
HF and all-cause mortality
through index
hospitalisation
Rate of combined end
point of CV death or
rehospitalisation for HF
or renal failure to day
60; days alive and out
of hospital to day 60
REVIVE I REVIVE II DOSE CARRESS ROSE
Clinicaltrials.gov Identifier NCT00048425 NCT00048425 NCT00577135 NCT00608491 NCT01132846
Enrolment period December 2001–
December 2004
December 2001–December
2004
March 2008–November
2009
June 2008–January
2012
September 2010–March
2013
Randomised treatments Levosimendan:
placebo (1:1)
Levosimendan: placebo
(1:1)
High-/low dose diuretic
IV bolus/IV infusion
diuretic (2×2 factorial)
Ultrafiltration medical
therapy (1:1)
Dopamine: nesiritide:
placebo (1:1:1)
Inclusion criteria
Age, years >18 >18 ≥18 ≥18 ≥18
Required history of HF No No Yes‡ No No
Time from presentation to
randomisation, hours
≤48 NR ≤24 ≤168 ≤24
LVEF, % ≤35 ≤35 NR NR NR
Dyspnoea requirements At rest At rest Rest/exertion NR NR
Other evidence of HF
(including symptoms, signs
and objective measures)
Can enrol >48 h if
deteriorates after initial
improvement with
conventional therapy
Persisting dyspnoea at rest
despite IV diuretic therapy
1 symptom and 1 sign of
HF daily oral furosemide
dose ≥80 ≤240 mg
Increase creatinine
>0.3 mg/dL ≥2
+peripheral oedema,
JVP >10 cm,
radiological pulmonary
congestion/oedema
eGFR ≥15 ≤60 mL/min/
1.73 m2 At least 1 sign
and symptom of HF
IV diuretic required before
randomisation
Yes Yes Yes Yes NR
Exclusion criteria
Systolic BP, mm Hg ≤90 ≤90 <90 <90 <90
Serum creatinine, mg/dL >5.0 >5.0 >3.0 >3.5 NR
eGFR, mL/min/1.73 m2 NR NR NR NR <15 or >60
Vasopressors/inotropes None PDE V inhibitors Both Both Both
Acute MI/ACS Angina in 6 h before
randomisation
Angina in 6 h before
randomisation
ACS within 4 weeks ACS within 4 weeks ACS within 4 weeks
Primary end point(s)
Improved/unchanged/
worse composite (24 h
and 5 days)
Clinical composite (6 h,
24 h and 5 days) 1. Patient global
assessment (VAS
AUC) at 72 h
2. change in Cr at 72 h
(safety)
Bivariate change in
weight/change in
creatinine (96 h)
1. Cumulative urine
volume (72 h)
2. change cystatin C
(72 h)
Continued
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Table 1 Continued
REVIVE I REVIVE II DOSE CARRESS ROSE
Secondary end point(s)‡‡
Change in BNP at 24 h
Change in PGA at 6 h
Change in dyspnoea at
6 h
DAOH
Death or worsening HF
NYHA class (day 5)
Mortality (90 day)
Change in BNP at 24 h
Change in PGA at 6 h
Change in dyspnoea at 6 h
DAOH
Death or worsening HF
NYHA class (day 5)
Mortality (90 day)
Patient dyspnoea report
Change in body weight
Net fluid loss
Proportion of patients
congestion free (72 h)
Increase serum Cr
>0.3 mg/dL (72 h)
Worsening/persistent HF
Change in biomarkers
(72 h/7 days/60 days)
Death/hosp/ER visit (day
60)
Days dead or
hospitalised (day 60)
Primary end point days
1–3, day 7
Weight loss and renal
function (96 h, 1 week)
Treatment failure
(7 days)
Change in renal
function (7 days,
30 days, 60 days); peak
creatinine
Change in electrolytes
(96 h, 1 week)
Change in weight
(1 week, 30 days,
60 days)
Proportion with clinical
decongestion (96 h,
1 week, 30 days,
60 days)
Total net fluid loss
(96 h, 1 week)
Change in biomarkers
(96 h, 1 week, 60 days)
Change in global
assessment and VAS
(96 h, 1 week)
LOS, DAOH, HF hosp,
ER visits, unscheduled
office visits
Change in diuretic dose
from admission
(discharge, 30 days,
60 days)
Resource utilisation
Change in Cr (72 h)
Cumulative urinary
sodium excretion (72 h)
PGA (72 h)
Dyspnoea (72 h)
Weight (72 h)
Change in BUN/cystatin
C ratio (72 h)
Increase in serum Cr
>0.3 mg/dL (72 h)
Persistent or worsening
HF (72 h)
Treatment failure (72 h)
*Prior diagnosis of HF on any oral therapy for same.
†A history of CHF (defined as requiring treatment for a minimum of 30d before hospitalisation).
‡A history of HF ≥14 days for which diuretic therapy has been prescribed.
§HF Score: dyspnoea (exertional=1 point, nocturnal=2 points, orthopnoea=3 points, rest=4 points)—maximum of four points. HR (91-110 bpm=1 point, >110 bpm=2 points)—maximum of two points. rales (bases only=1
point, >bases=2 points)—maximum of two points. Right heart ( JVP >6 cm=1 point, JVP >6 cm with oedema or hepatomegaly=2 points)—maximum of two points.
¶HF symptoms at rest or minimal exertion.
**Except dopamine ≤2 μg/kg/min or digitalis during the current hospitalisation.
††Excluded if: received first IV treatment of diuretics, VD or inotropes for HF >24 h before randomisation; treated with levosimendan or milrinone within 30 days before randomisation or anticipated need for these during
current hospitalisation; treated with IV vasoactive medication where the dosage is not stable for 3 h before randomisation; treated with dobutamine ≥5 μg/kg/min at the time of randomisation.
‡‡Not exhaustive.
ACS, acute coronary syndrome; AHF, acute heart failure; ARB, angiotensin receptor blocker; AUC, area under the curve; ASCEND, acute study of clinical effectiveness of nesiritide in decompensated heart failure; BP,
blood pressure; CV, cardiovascular; CABG, coronary artery bypass graft; CHF, heart failure; COPD, chronic obstructive pulmonary disease; CARRES, cardiorenal rescue study in acute decompensated heart failure; CXR,
chest x-ray; DAOH, days alive and out of hospital; DOSE, diuretic optimization strategies evaluation; EF, ejection fraction; Egfr, estimated glomerular filtration rate; ER, days alive and out of hospital; EVEREST, the efficacy
of vasopressin antagonism in heart failure outcome study with tolvaptan; Hosp, hospital; HF, heart failure; ICD, implantable cardiac defibrillator; IV, intravenous; JVP, jugular venous pressure; LVSD, left ventricular systolic
dysfunction; LOS, length of stay; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NK, not known; NT, n-terminal; NR, not required; NYHA, new york heart
association; OPTIME, the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure; PDE, phosphodiesterase inhibitor; PCI, percutaneous coronary intervention; PCWP, pulmonary
capillary wedge pressure; PGA, patient global assessment; ProBNP, pro b-type natriuretic peptide; PROTECT, placebo-controlled randomised study of the selective A1 adenosine receptor antagonist rolofylline; Pts,
patients; STEMI, ST-segment elevation myocardial infarction; SURVIVE, the survival of patients with acute heart failure in need of intravenous inotropic support; RELAX-AHF, the RELAXin in acute heart failure; RR,
respiratory rate; REVIVIE, randomized evaluation of intravenous levosimendan efficacy; ROSE, renal optimization strategies evaluation; VAS, visual analogue score; VERITAS, the value of endothelin receptor inhibition
with tezosentan in acute heart failure studies; VD, vasodilators.
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Table 2 Baseline characteristics
Variable
OPTIME
(n=949)
SURVIVE
(n=1327)
VERITAS
(n=1435)
EVEREST
(n=4133)
PROTECT
(n=2033)
ASCEND-HF
(n=7007)
RELAX-AHF
(n=1161)
REVIVE I
(n=100)
REVIVE II
(n=600)
DOSE
(n=308)
CARRESS
(n=188)
ROSE
(n=360)
Demographic
Mean age, years 66 67 70 66 70 67* 72 59 64 66 68* 70*
Female sex, % 29 28 40 26 32 34 38 23 27 27 25 27
White race, % 65 94 86 86 95 56 94 60 65 75 70 79
Black race, % 33 NK 8 8 NK 15 NK NK NK 25 30 21
Mean time from admission to
randomisation, hours
15.3 NK 12.2 NK NK 15.5* 7.9 NK NK 14.6* 34* 24
Location, %
USA/Canada 100 0 22 30† NK 45† 10 NK NK 100 100 100
Non-USA/Canada 0 100 78 70 NK 55 90 NK NK 0 0 0
Physiological measures (mean)
BMI (kg/m2) NK 28 29 29 29 28* 29 NK NK NK NK 31*
RR, bpm NK NK 26 NK 21 24* 22 NK NK NK NK NK
HR, bpm 85 84 82 80 80 82* 80 84 82 78 NK NK
Systolic BP, mm Hg 120 116 131 121 124 123* 142 115 116 120 NK 115*
Diastolic BP, mm Hg 71 70 72 73 74 74* 82 69 69 NK NK NK
Cardiac
Mean LVEF, % 24 24 27 28 32 30* 39 20 24 35 33* 33*
LVEF ≥40%, % NK NK 53 NK NK 20 49 0 0 NK NK NK
Mean BNP, pg/mL NK 1624 1673 NK 1016* 992* NK NK NK NK NK NK
Mean NT-proBNP, pg/mL NK NK 11692 4263 3000* 4463* 5064‡ NK NK 7439 4510 5017*
Ischaemic aetiology of HF, % 51 76 68 65 NK 48 NK NK NK 57 61 58
Prior HF hospitalisation, % NK NK NK 79 NK 39§ 34§ NK NK 74 77 67
Biochemistry (mean)
Blood urea nitrogen, mg/dL 11.4 NK 27.0 30.2 34.1 9.0* 27.2 NK NK 37.5 49.6 36
Serum sodium, mEq/L 138 138 139 140 NK 139* NK NK NK 138 NK NK
Serum creatinine, mg/dL 1.4 1.6 1.3 1.4 1.5 1.2* 1.3 NK NK 1.5 2.0 NK
eGFR, mL/min per 1.73 m2 NK NK NK NK 50.6 CC NK 53.5 NK NK NK NK 42*
Co-morbidity, %
History of HF NK 88 73 NK NK 39¶ NK NK NK NK NK NK
Hypertension 68 63 79 71 79 72 87 NK NK NK 85 83
Myocardial infarction 48 68 52 51 49 35 NK NK NK NK NK NK
Atrial fibrillation 32 48** 37 43 55 38** 52** NK NK 53 NK 60
Mitral regurgitation 47 63 12 32 NK NK 31 NK NK NK NK NK
PCI/CABG 18/31 NK 22 18/21 NK NK NK NK NK NK NK NK
ICD 8 4 7 15 16 16 13 NK NK 39 NK 43
Stroke 15 NK 16 11 NK 12 14 NK NK NK NK NK
Diabetes mellitus 44 32†† 48 39 45 43 48 NK NK 52 66 55
COPD/asthma 23/- NK 19/- 10/- 20 16/- 16 NK NK NK NK NK
OPTIME SURVIVE VERITAS EVEREST PROTECT ASCEND-HF RELAX-AHF REVIVE I REVIVE II DOSE CARRESS ROSE
Pre-admission treatments, %
ACE-inhibitor/ARB 70/13 69 NK NK 76 NK NK 74 77 64 54 50
MRA NK 53 NK NK 44 NK NK 35 37 28 20 30
Continued
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caused only a slight decrease in systolic blood pressure
(SBP).13 These properties are of course, relevant when
considering the underlying pathophysiology of AHF.
In a phase II, placebo-controlled dose-ranging study
(Pre-RELAX-AHF) the potential therapeutic beneﬁts of
serelaxin were recognised.14 In that pilot study, patients
receiving the 30 μg/day dose experienced greater dys-
pnoea relief compared with placebo. These positive ﬁnd-
ings supported the undertaking of a larger-scale
mortality/morbidity trial.
In comparison to other drugs that have been tested for
use in AHF, serelaxin seems unique. Other drugs share its
vasodilator actions (eg, nesiritide, tezosentan, milrinone
and levosimendan) but none have reduced postdischarge
mortality.12 Several of these drugs (notably milrinone and
levosimendan) have an inotropic action and this, in itself,
may be associated with an increased risk of death. At the
very least, doubts still remain regarding the overall safety
of these agents. Even if the inotropic drugs are discounted,
why did the other vasodilators such as nesiritide and tezo-
sentan fail? One possibility is that previous AHF trials
included patients unlikely to beneﬁt from the effects of
these drugs on account of on their AHF proﬁle.
PATIENT POPULATION
The other trials did not fail because they were too small
and underpowered. EVEREST and the ASCEND-HF
trials, for example, were much larger.9 10 The patients
enrolled in RELAX-AHF were a speciﬁc subset of
patients with AHF not previously included in other
trials. This distinct cohort may have been more likely to
beneﬁt from the haemodynamic effects of serelaxin.4
The baseline characteristics of the patients enrolled in
RELAX-AHF compared to those enrolled in other AHF
trials are summarised in table 2. In RELAX-AHF,
patients with a SBP of ≤125 mm Hg were excluded. In
the 1161 patients included, the mean SBP was approxi-
mately 142 mm Hg—higher than equivalent values from
previous studies. As demonstrated in the REVIVE II
trial,3 low SBP at baseline is associated with increased
in-hospital and postdischarge mortality and to avoid this
adverse outcome, RELAX-AHF enrolled a set of patients
with a lower baseline risk.4 In fact, as shown in table 2,
87% of patients in RELAX-AHF had a history of hyper-
tension. Not only were potential participants excluded if
their baseline SBP was too low, careful attention was also
paid to any fall in SBP during the trial. If SBP decreased
by more than 40 mm Hg from baseline, but remained
greater than 100 mm Hg, the study drug infusion rate
was halved for the remainder of the infusion period.
The study drug infusion was discontinued if SBP
dropped below 100 mm Hg. These additional measures
may too have contributed to the overall tolerability of
the study drug.
Another notable difference between RELAX-AHF and
the other AHF trials was the inclusion of patients irre-
spective of left ventricular ejection fraction (LVEF).T
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Patients with HF and preserved ejection fraction
(HF-PEF) represent up to half of all patients admitted
with AHF. No HF treatment has been shown to be as
effective in HF-PEF to date. With the exception of the
PROTECT study, all other AHF trials excluded patients
with HF-PEF (table 1). In RELAX-AHF ejection fraction
was available for most patients with the mean being 39%
and 45% of patients having a LVEF ≥40%. At presenta-
tion these patients had higher recordings of mean SBP
and lower concentrations of NT-pro BNP, troponin T
and serum creatinine.
Serelaxin induced a similar dyspnoea relief in both
groups, according to visual analogue score (VAS)-AUC
(mean AUC change, 461 vs 397 mm×h, respectively). It
also exhibited similar effects on CV death or hospitalisa-
tion for heart or renal failure at day 60, days alive and
out of hospital at day 60 and CV death at day 180.15
Pathophysiological changes including increased LV after-
load, pulmonary congestion and end-organ damage are
common to HF-REF and HF-PEF. Although, this does
not explain the failure of the other trials, it suggests that
the beneﬁcial effects seen with serelaxin may be
explained by its systemic vascular effects.
While some of the other AHF trials analysed in this
review excluded patients with varying degrees of renal
dysfunction, RELAX-AHF included patients with an
eGFR between 30 and 75 mL/min/1.73 m2.16 Worsening
renal function (serum creatinine increase of ≥0.3 mg/dL
(27 µmol/L) or cystatin-C increase of ≥0.3 mg/L
(22 nmol/L) at day 2) occurred in 15.4% and 19.6% of
patients, respectively.17 These measures of worsening
renal function were associated with higher 180 day all-
cause mortality. Baseline values in serum creatinine were
similar between the placebo and serelaxin groups,
however, patients receiving serelaxin had signiﬁcantly
lower serum creatinine and cystatin-C levels at day 5. The
serelaxin group had a lower incidence of worsening renal
function at day 2 and lower levels of blood urea nitrogen
and uric acid each day from day 1 to day 5. Serelaxin
administration was therefore associated with lower
markers of renal dysfunction and reduced incidence of
worsening renal function, consistent with the hypothesis
that the prevention of renal dysfunction during AHF hos-
pitalisation, favourably inﬂuences outcomes.17
To reduce the chance of enrolling patients without
pulmonary congestion, RELAX-AHF included raised
baseline serum biomarkers (NT-pro BNP ≥1400 ng/L or
BNP ≥350 ng/L) as part of the study inclusion criteria
(mean NT-pro BNP 5064 ng/L). This is in contrast to
the other AHF trials, none of which stipulated raised
biomarker levels as being compulsory for inclusion. Of
the other trials, only ASCEND-HF and VERITAS
included raised BNP or NT-pro BNP as a potential route
of enrolment. As this was optional, not all patients quali-
ﬁed for enrolment on this basis and in fact only 18%
and 2% of patients in VERITAS had a raised BNP or
NT-pro BNP, respectively, with the mean serum BNP at
baseline being 590 pg/mL.11 18 This may reﬂect a
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potentially important difference between the popula-
tions studied.
A recent trial in chronic HF illustrates the potential
value of using natriuretic peptides to select patients for
trials. The TOPCAT investigators randomly assigned
patients to receive either spironolactone or placebo and
this randomisation was stratiﬁed according to whether
patients were enrolled on the basis of prior hospitalisa-
tion within the previous 12 months (hospitalisation
stratum) or an elevated natriuretic peptide level within
60 days before randomisation (BNP stratum).19 They
found that the study drug effects differed signiﬁcantly
according to randomisation stratum (p=0.01 for inter-
action). In the hospitalisation stratum, spironolactone
had no effect on time to the composite outcome of
death from CV causes, aborted cardiac arrest or hospital-
isation for HF (HR, 1.01; 95% CI 0.84 to 1.21; p=0.92)
whereas in the BNP stratum, spironolactone did show
beneﬁt (HR, 0.65; 95% CI, 0.49 to 0.87; p=0.003). These
ﬁndings illustrate the potential importance of natriuretic
peptide levels as a predictor of adverse outcomes in HF
and their value as an inclusion and quality criterion in
clinical trials—especially in the setting of HF-PEF which
remains difﬁcult to deﬁne.
The inclusion/exclusion criteria of RELAX-AHF also
resulted in the selection of a relatively homogeneous
population: older patients, with HF who were more
likely to have hypertension than CAD. Other AHF trials
may have enrolled a more heterogeneous population
with subsets of patients that might not respond to
therapy.
OTHER DESIGN ASPECTS OF TRIAL
RELAX-AHF was generally similar in terms of the ele-
ments of study design compared with previous AHF
trials, as shown in table 1. The main similarities being:
evidence of AHF, dyspnoea requirements, exclusion of
patients receiving inotropes and exclusion of patients
with on-going myocardial ischaemia.
However, there are some fundamental yet subtle differ-
ences. First, RELAX-AHF enrolled patients relatively
early after presentation that is, within 16 h. We know
that early intervention has the best chance of achieving
symptomatic improvement as it is during this time that
organ damage and congestion may exert long-term
adverse effects. Other AHF trials have failed to recruit
patients this early on. A shift from typical entry criteria
and better communication between departments (eg,
emergency and cardiology departments) may be neces-
sary to streamline enrolment—allowing for early ran-
domisation in future trials.
Although there was no difference in the effect of sere-
laxin according to time from admission to randomisa-
tion in RELAX-AHF,20 patients assigned to serelaxin
received a signiﬁcantly lower average dose of intravenous
loop diuretic (p=0.006) and fewer received other vaso-
active drugs (p=0.01) up to day 5, compared with the
placebo group. This may have reﬂected the overall rapid
time to randomisation, with less need for escalation of
conventional treatment in patients receiving serelaxin.
Less use of conventional treatment in the serelaxin
group may have contributed to the beneﬁt of experi-
mental therapy as higher doses of diuretics and the use
of some vasoactive agents (ie, inotropes) is associated
with worse outcomes.
The notion of initiating therapy as early as possible is
not something that is new to cardiology. Most notably,
this was demonstrated in reducing the time for patients
receiving thrombolysis followed by PCI in the context of
acute STEMI; the phrase ‘time is muscle’ being familiar
to all cardiologists. As with acute coronary syndromes,
we know that release of troponin in AHF represents
myocardial injury and that elevated levels are associated
with poorer long-term outcomes. A substudy of
RELAX-AHF studied biomarkers representative of end
organ damage including: high-sensitivity troponin
(cardiac), serum creatinine and cystatin-C (renal), trans-
aminases (liver), and NT-proBNP (congestion).17
This substudy ﬁrst conﬁrmed that elevated serum high-
sensitivity troponin values at baseline were associated with
increased 180-day all-cause mortality. Patients treated with
intravenous serelaxin had reduction in their troponin
levels at day 2 postrandomisation—potentially providing a
mechanism for the improved long-term survival seen in the
serelaxin treated group. However, to be valid, this hypoth-
esis requires the myocardial injury sustained during admis-
sion to be substantial enough to lead to progressive
worsening of ventricular function and HF status over time.
It is perhaps easier to understand that recurrent admissions
could lead to a downward spiral in this way. Markers of
renal dysfunction, liver dysfunction and congestion were all
reduced at day 2 in patients treated with intravenous sere-
laxin as was the other prespeciﬁed efﬁcacy analysis looking
at early worsening of HF. Signiﬁcantly fewer patients in the
serelaxin treated group experienced worsening of HF up
to day 5 and there was a 30% reduction in the hazard of
worsening HF in the ﬁrst 14 days. Although worsening HF
was not an adjudicated event in RELAX-AHF, the ﬁnding
that serelaxin seemed to reduce the risk of this occurrence
has led to a great deal of debate about the importance of
worsening of HF (or persistence or worsening) during the
patient’s admission. Patients exhibiting worsening have a
longer length of stay, higher in-patient and postdischarge
mortality and an increased risk of readmission (compared
those who do not experience worsening during their index
admission). Whether in-patient worsening is a useful end
point for future trials in AHF is presently the subject of
regulatory discussion.21 22
END POINTS INCLUDING DYSPNOEA
Dyspnoea is the most commonly reported symptom in
AHF. Despite this, its pathophysiology is poorly under-
stood and there is no standardised assessment method.
Although the use of dyspnoea as an end point in AHF
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trials has become prominent over the years, there is sub-
jectivity related to its evaluation and measurement.
Typical assessments include a VAS, a Likert scale or
both. Past studies suggest that the VAS better captures
changes in dyspnoea over time although a number of
factors (including patient positioning) during measure-
ment affect responses.23 Previous studies have also
shown signiﬁcant differences in patient responses
between the two scales, suggesting poor inter-scale reli-
ability. Dyspnoea improves rapidly in response to conven-
tional therapy, making it difﬁcult to show incremental
beneﬁt with novel treatments.24 25
Relief of dyspnoea is a key goal of treatment in
patients with acute pulmonary oedema and historically
is an accepted end point in acute HF trials.26 However, it
is clear that the use of dyspnoea as an end point is
much more complex than originally thought. First, con-
ventional therapy seems to lead to rapid relief of dys-
pnoea in most patients (at least as usually measured). It
is difﬁcult therefore, for any new treatment, added to
usual therapy, to show more rapid or greater (or both)
relief of dyspnoea (or greater relief in a larger propor-
tion of patients more quickly). Certainly, starting a new
treatment relatively late after presentation may ‘miss the
therapeutic boat’. Apart from trying to start the new
intervention as early as possible, the other obvious
approach would be to compare the new treatment to
existing therapy (rather than add to it); however, there
has been so much reluctance to withhold conventional
treatment (ie, mainly intravenous diuretic) this has
never been done in any large trial. We do not know why
this convention has never been broken—we do not
think to take such an approach is unethical and ‘rescue
therapy’ could be permitted (and even be part of a
study end point). It is also possible that a new therapy
might not result in more rapid (or greater) dyspnoea
relief but could achieve the same relief more safely—this
is certainly a possibility given that there is concern
among some that diuretics and other treatments (eg,
inotropes) may be harmful in AHF, even if they relieve
symptoms. Indeed, it is a pre-requisite that any new treat-
ment shown to relieve dyspnoea must also demonstrate
safety.
There is also uncertainty about how best to measure
dyspnoea relief and simple provocation by placing the
patient supine or using exercise may demonstrate that
relief of dyspnoea may not be nearly as complete as
when the patient is assessed in an upright or semirecum-
bent position.27 Standardisation of the circumstances of
measurement of dyspnoea has not been given the atten-
tion it deserves and it is still not clear to the authors
which instrument is best for measurement of dyspnoea
(eg, Likert scale or VAS). The measurement tools com-
monly used also create an additional problem; what is
the clinical importance of a few mm difference in a VAS
or half a point on a Likert scale? In particular, what is its
economic value? So while dyspnoea relief is undoubtedly
important to patients, showing a clinically and
economically worthwhile beneﬁt is an extremely challen-
ging proposition and it is our view that while relief of
this symptom will remain an end point in trials, ‘harder’
clinical end points (eg, worsening heart failure, readmis-
sion and death) and economic outcomes (eg, length of
stay) are likely to become much more important in the
future.
In RELAX-AHF both of the primary end points were
related to dyspnoea. First, the change in dyspnoea from
baseline to day 5 using the VAS (quantiﬁed by AUC) was
measured. This primary end point proved to be success-
ful, reaching statistical signiﬁcance, with a mean differ-
ence of 448 mm×h in the AUC in serelaxin treated
patients; however, improvement was largely driven by
imputation of a worst (zero) score for patients treated
for worsening HF. Second, dyspnoea was measured at 6,
12 and 24 h using a seven-point Likert scale. The
improvement in this coprimary end point was non-
signiﬁcant, although positive ﬁndings were noted at
each individual time interval in the active group.
Table 3 highlights the variation in dyspnoea assess-
ment tools used in the other studies. In addition to
RELAX-AHF, the only other study to show improvement
in dyspnoea (as measured by the VAS) was the DOSE
trial. Of the remaining studies which used the seven-
point Likert scale to determine change in dyspnoea
status, EVEREST, REVIVE and ASCEND-HF showed
improvement (although this did not reach statistical sig-
niﬁcance in ASCEND-HF). It is difﬁcult to interpret
these results given the lack of a standardised tool. This
may introduce unwanted variability and confound
attempts to demonstrate efﬁcacy of treatment.
MORTALITY
There was a puzzling divergence between the effect of
serelaxin on mortality and heart failure/renal hospital-
isation in RELAX-AHF. No satisfactory explanation has
been found for this. However, a larger proportion of
patients in the serelaxin group had a hospital admission
for HF within a year prior to enrolment, compared with
the placebo group—and recent HF hospitalisation is the
single most powerful predictor of readmission. It should
be noted, however, that the hospital readmission rates
were only measured up to day 60 and different results
may have been found if they were assessed at 180 days
(as was the case with mortality alone). There is also the
issue of competing risks, whereby the greater survival in
the serelaxin group leaves more patients (and poten-
tially sicker patients) in that group at risk of
hospitalisation.
The most remarkable ﬁnding from RELAX-AHF was
the possible 37% reduction in CV and all-cause mortality
at 180 days in the serelaxin treated group compared to
placebo. This ﬁnding, if true, is astonishing given that
no other AHF trial ever showed a positive effect on long-
term survival. This result raises an important question:
how is it possible for a drug infusion given for 48 h to
Cannon JA, McKean AR, Jhund PS, et al. Open Heart 2015;2:e000283. doi:10.1136/openhrt-2015-000283 9
Heart failure and cardiomyopathies
group.bmj.com on January 12, 2016 - Published by http://openheart.bmj.com/Downloaded from 
have a positive effect on survival at 180 days? The answer
to this is unclear. However, it is postulated that early
intervention may ameliorate the ‘neurohormonal storm’
that is thought to characterise AHF. This intervention
may prevent further damage to vital organs and, over a
period of time, this is translated to long-term beneﬁt in
terms of improved survival.4 17 The biomarker data
alluded to above give some support for this hypothesis.
However, some have been sceptical of this mortality
ﬁnding especially given that rehospitalisation rates were
not reduced in the serelaxin group, compared with the
placebo group. This concern is based on the evidence
that other drugs shown to reduce mortality in HF also
reduce HF hospital admissions (although we only know
this from CHF trials).28
It has also been highlighted that the serelaxin treat-
ment group, at baseline, were at higher risk of rehospita-
lisation compared to placebo due to a greater
percentage of patients being admitted to hospital for HF
in the past year (37% of patients in the serelaxin treat-
ment group vs 31% of patients in the placebo group).
Given the dispute surrounding this ﬁnding,
RELAX-AHF 2 is currently underway in an attempt to
replicate these results. This double-blind randomised
trial is projected to enrol up to 6800 patients and will
therefore be sufﬁciently powered to detect an effect on
mortality.29 It aims to conﬁrm and expand the efﬁcacy,
safety and tolerability evidence of 48 h intravenous infu-
sion of serelaxin (30 μg/kg/day) when added to stand-
ard care in patients admitted with AHF.29
CONCLUSIONS AND FUTURE IMPLICATIONS
While RELAX-AHF has demonstrated the possible efﬁ-
cacy of a novel therapeutic agent, these results were
undoubtedly helped by adopting a more modern
approach to study design. The concept of targeting a
speciﬁc population is something that has been suggested
before. By enrolling a more homogenous group with
AHF, beneﬁts from treatment with serelaxin—mediated
by its predominantly vascular mode of action—were
more likely to occur than in patients with AHF and
other diverse clinical characteristics. This raises concerns
regarding the generalisability of these results and
emphasises the need for further evidence demonstrating
its efﬁcacy in other common clinical scenarios for
example, the patient with AHF with hypotension. This
trial has also highlighted the challenge of attempting to
improve dyspnoea against standard therapy and has
shown the need for future trials to move away from dys-
pnoea as an end point and to focus to harder outcomes
such as long-term survival.
Ularitide (a synthetic analogue of urodilatin) has pre-
viously been trialled in two double-blind placebo-
controlled, proof-of-concept pilot studies and demon-
strated encouraging on haemodynamics and symptoms.
TRUE-AHF is a phase III clinical trial examining the efﬁ-
cacy and safety of ularitide as a treatment for AHF.30
The study has randomised over 2000 patients within
12 h of admission and the trial has two co-primary efﬁ-
cacy end points. One is a hierarchically constructed end
point ranking patients as better, worse or unchanged
over a ﬁxed time period with the ranking dependent on
patient global assessment, persistent or worsening HF
requiring intervention and death. The other evaluates
freedom from CV mortality during follow-up after ran-
domisation for the duration of the trial.
Omecamtiv mecarbil (a selective cardiac myosin activa-
tor) enhances binding of actin to myosin and in so
doing prolongs systole. Phase I and II testing has been
completed and the compound was well tolerated (in the
absence of tachycardia). These data were sufﬁcient to
proceed with the phase IIb trial (ATOMIC-AHF), the
aim of which was to evaluate the effect of 48 h of intra-
venous omecamtiv mecarbil compared with placebo on
dyspnoea in subjects with LVSD hospitalised for AHF.31
Although this trial failed to achieve its primary end
point, it did provide essential information to inform the
dosing regimen for future phase III trials.
Completed trials in AHF with neutral or negative
results, though disappointing, contribute to our overall
knowledge regarding clinical characteristics and out-
comes, and they can inﬂuence the design of future
trials. We await the results of ongoing and new AHF
trials to determine whether effective and safe therapies
are on the horizon. In the future, attempts should be
made to match patient characteristics with the expected
pharmacological mechanism of action for new agents,
rather than taking the traditional ‘all comers’ approach.
Successful translation of this approach into a greater
ability to demonstrate the effectiveness of therapies
remains to be seen. Consideration must also be given to
the timing of intervention to determine the optimal
‘window of opportunity’. Although advances have been
realised, many opportunities remain to reduce the
burden of AHF.
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